EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
獨家：Roundhill Investments推出減肥ETF，用於投資Ozempic等重磅藥物
Roundhill Investments launched a new exchange-traded fund (ETF) Tuesday.
朗德希爾投資週二推出了新的交易所交易基金（ETF）。
What Happened: The Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) marks a significant milestone as the world's first GLP-1 ETF.
發生了什麼：朗德希爾 GLP-1 和減肥ETF（納斯達克股票代碼：OZEM）作爲世界上第一個 GLP-1 ETF，標誌着一個重要的里程碑。
Roundhill asserts that weight loss drugs, particularly GLP-1 agonists, are among the most revolutionary advancements in the global pharmaceuticals industry.
朗德希爾斷言，減肥藥物，特別是 GLP-1 激動劑，是全球製藥行業最具革命性的進步之一。
Notably, OZEM is the only ETF providing dedicated exposure to transformative weight loss stocks such as Eli Lilly & Co. (NYSE:LLY), the producer of Zepbound, and Novo Nordisk A/S (NYSE:NVO), the maker of Ozempic.
值得注意的是，OZEM是唯一一家專門投資禮來公司等變革性減肥股票的ETF。Zepbound的製片人紐約證券交易所代碼：LLY）和Ozempic的製造商諾和諾德A/S（紐約證券交易所代碼：NVO）。
"These new treatments work incredibly well," Roundhill CEO Dave Mazza told...
朗德希爾首席執行官戴夫...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。